S3V Vascular Technologies Unlisted Shares
S3V Vascular Technologies – Series B Funding from AM Naik, Madhusudan Kela & Others
The Economic Times
2 min read
Expert Analysis:
S3V Vascular has secured Series B funding from prominent investors including L&T Chairman Emeritus A.M. Naik, Madhusudan Kela, Utpal Sheth (Rare Enterprises), and other ultra-high net worth individuals, reflecting strong institutional and investor confidence in the medical device import-substitution opportunity.
The company is establishing an integrated manufacturing facility to produce neurovascular devices including stent retrievers, microcatheters, and guidewires for India's stroke care market, with plans to scale production capacity significantly.
S3V's strategy includes pursuing international regulatory approvals (USFDA, CE certifications) to enable exports to Asia, Latin America, and Europe, and partnering with hospitals and public health systems including Ayushman Bharat to improve access to affordable thrombectomy procedures across India.
Key Takeaway:
S3V Vascular's high-caliber investor backing and focus on indigenizing high-end stroke-care devices position it as a significant healthcare import-substitution play, though scaling manufacturing, achieving regulatory clearances, and securing hospital adoption remain critical execution milestones.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved